Journals / Anadolu Kardiyoloji Dergisi / 2010 / Cilt: 10 - Sayı: 1

Comparative effects of losartan and nifedipine therapy on exercise capacity, Doppler echocardiographic parameters and endothelin levels in patients with secondary pulmonary hypertension

Sekonder pulmoner hipertansiyonu bulunan hastalarda losartan ve nifedipin tedavisinin egzersiz kapasitesi, Doppler ekokardiyografi parametreleri ve endotelin düzeylerine etki açısından karşılaştırılması

Pages
43–49
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: When posttreatment values were compared with baseline values in both groups, the following statistically significant changes were noted: the mean values of both mean and systolic pulmonary artery pressures (PAPs) were reduced (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Pulmonary hypertension (PHT) is associated with high mortality and morbidity.
📊
Key Findings & Data:Interest has increased in the use of drugs that, because of their neurohumoral inhibitory effects, inhibit the renin angiotensin system.
💡
Conclusion & Impact:Results: When posttreatment values were compared with baseline values in both groups, the following statistically significant changes were noted: the mean values of both mean and systolic pulmonary artery pressures (PAPs) were reduced (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Pulmonary hypertension (PHT) is associated with high mortality and morbidity. Interest has increased in the use of drugs that, because of their neurohumoral inhibitory effects, inhibit the renin angiotensin system. In this study, we sought to examine whether losartan therapy is non-inferior to nifedipine in the treatment of secondary PHT. Methods: This prospective randomized study consisted of 63 patients (mean age, 63.7±9.1 years) with PHT who underwent Doppler echocardiographic examination. A baseline 6-minute walk test (6MWT) and cardiopulmonary exercise test (CPET) were performed, and the endothelin-1 level of each patient was measured. Patients were assigned to two groups receiving treatment with nifedipine (n=30) and losartan (n=33). After 2 months of treatment, those measurements were repeated. The groups were compared with regard to effectiveness for the studied parameters using 2*2 factorial ANOVA design for repeated measurements. Results: When posttreatment values were compared with baseline values in both groups, the following statistically significant changes were noted: the mean values of both mean and systolic pulmonary artery pressures (PAPs) were reduced (p

Özet

Amaç: Pulmoner hipertansiyon (PHT) artmış mortalite ve morbidite ile ilişkilidir. Nörohumoral inhibitor etkileri nedeniyle renin-anjiyotensin sistemini bloke eden ilaçlara ilgide bir artış dikkati çekmektedir. Bu çalışmada losartan tedavisinin nifedipinden daha az etkili bir ajan olup olmadığının araştırılması amaçlanmıştır. Yöntemler: Bu çalışmaya Doppler ekokardiyografi ile PHT saptanan 63 hasta (ortalama yaş 63.7±9.1) dahil edildi. Bazal durumda 6 dk yürüme testi ve kardiyopulmoner egzersiz testi (KPET) yapıldı, endotelin-1 düzeyleri çalışıldı. Tüm hastalar aldıkları tedaviye göre 2 gruba ayrıldı: nifedipin (n=30) ve losartan (n=33). İki aylık tedaviden sonra bu ölçümler tekrarlandı. Gruplar, tekrarlayan çalışılmış parametrelere olan etkinlik açısından 2*2 faktöryel dizayn ANOVA testi ile karşılaştırıldı. Bulgular: Tedavi öncesi ile karşılaştırıldığında her iki grupta sistolik ve ortalama pulmoner arter basıncı anlamlı şekilde daha düşük (p

🔖

Cite This Article

ULUBAY, G., BOZBAŞ, S. Ş., EYÜPOĞLU, Ö. F., ATAR, A., BOZBAŞ, H. (2022). Comparative effects of losartan and nifedipine therapy on exercise capacity, Doppler echocardiographic parameters and endothelin levels in patients with secondary pulmonary hypertension. Anadolu Kardiyoloji Dergisi, Cilt: 10 - Sayı: 1, 43–49. https://ajindex.com/articles/436816

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006
  2. doi:10.1378/chest.129.3.746 PMid:16537877 2. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992
  3. PMid:1603139 3. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005
  4. doi:10.1161/CIRCULATIONAHA.104.488486 PMid:15939821 4. Morrell NW, Higham MA, Phillips PG, Shakur BH, Robinson PJ, Beddoes RJ. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. Respir Res. 2005
  5. Oh JK, Seward JB, Tajik AJ. The Echo Manual. 2nd ed. Baltimore, MD: Lippincott Williams & Wilkins, 1999. 5. Oh JK, Seward JB, Tajik AJ. The Echo Manual. 2nd ed. Baltimore, MD: Lippincott Williams & Wilkins, 1999. 6. Otto CM. Textbook of Clinical Echocardiography. 3rd ed. Philadelphia, PA, Elsevier Saunders, 2004. 7. Wasserman K, Hansen J, Sue DY, Whipp BJ. Principles of exercise testing and interpretation. 3rd ed. Baltimore, MD: Lippincott, Williams and Wilkins, 1999. 8. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 2001
  6. doi:10.1016/S0163-7258(01)00157-7 9. Anand IS, Chandrashekhar Y, Ferrari R, Sarma R, Guleria R, Jindal SK, et al. Pathogenesis of congestive state in chronic obstructive pulmonary disease. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Circulation 1992
  7. PMid:1617764 10. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989
  8. PMid:2805258 11. Nong Z, Stassen JM, Moons L, Collen D, Janssens S. Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Circulation 1996
  9. PMid:8873672 12. Zakheim RM, Mattioli L, Molteni A, Mullis KB, Bartley J. Prevention of pulmonary vascular changes of